Acurion, a San Diego-based AI developer, has raised $4.3M in an oversubscribed seed round led by TK & Partners. OncoGaze predicts actionable genomic biomarkers like HRD from routine H&E pathology slides in minutes, enabling faster precision oncology without NGS delays. The funds will support clinical validation, platform development, regulatory preparation, and commercialization.
PathAI Series C Ignites AI Pathology Funding
The raise aligns with surging investor interest in AI pathology. PathAI secured $165M Series C in February 2026 to scale its platform, while Ibex Medical Analytics launched Ibex 4 for cancer workflows in March 2026. Acurion's focus on biopsy-stage genomic predictions from standard slides targets a key gap in immediate therapy decisions. Recent FDA breakthrough designations, like PathAI's for dermatopathology, signal regulatory momentum for such tools.
NGS Delays Block Precision Therapy Access
Next-generation sequencing for biomarkers like HRD takes weeks and misses patients due to tissue limits and costs. Fewer than 5% of eligible patients access precision therapies despite over 100 FDA approvals per company analysis. OncoGaze detects 1.8-3.1x more HRD-positive patients than NGS from routine slides. This addresses critical timing in aggressive cancers like ovarian and pancreatic.
OncoGaze Unlocks Biomarkers from H&E Slides
OncoGaze uses deep learning to analyze mutational signatures in pathology images, delivering NGS-equivalent insights instantly via cloud. Unlike broader platforms like Tempus, it specializes in HRD for ovarian, breast, and pancreatic cancers, with pipeline expansions to KRAS, EGFR, and MMRD. A July 2024 Journal of Clinical Oncology publication validated its efficacy. The UCSD-spunout technology holds 5 patents pending.
As TK & Partners Chairman Tomas Koch noted:
"Acurion stood out immediately — tackling a global problem with a strong technical edge."
Oversubscribed Round Draws Precision Experts
The round exceeded its $4M target with participation from Mesa Verde Venture Partners, National Foundation for Cancer Research, Asian Fund for Cancer Research, and Bootstrap Ventures. Investors signal conviction in Acurion's team and tech amid AI pathology adoption. Lead backer TK & Partners highlights the platform's potential to identify up to 3x more patients in hours versus weeks.
Digital Pathology Market Scales Rapidly
The digital pathology market stands at $1.39B in 2026, projected to reach $2.76B by 2035 at 7.99% CAGR per Precedence Research. Precision oncology opportunities exceed $141B with 12.9% CAGR according to market reports. Competitors like Paige AI, acquired by Tempus for $81M, underscore consolidation in biomarker prediction from H&E.
Serial Exits Anchor Oncology Expertise
Co-founders François Ferré and Magda Marquet bring proven exits: AltheaDx acquired by Castle Biosciences for $65M upfront (up to $140M) in 2022, and Althea Technologies by Ajinomoto for ~$175M in 2013. Advising CCO Mike Hoerres founded Cernostics, sold to Castle for $30M upfront (up to $80M) in 2021. New VP Product David Schlesinger led SOPHiA Genetics' AI HRD solution. This team translates AI pathology into commercial diagnostics.
PanCAN Partnership Fuels Clinical Push
Acurion plans expanded clinical collaborations, including its Pancreatic Cancer Action Network partnership from July 2025. Funds enable regulatory milestones and national lab deployments. Recent HLTH 2025 award as Rising Star in AI Patient Care bolsters path to market.